Biotech pipeline news and biotech drug news continues to hit. A report from Bank of America/Merrill Lynch is highlighting four small-cap to mid-cap biotech stocks with positive prescription trends so far in 2013. The analyst report, led by Steve Byrne, is actually mixed in the stocks to buy case. This Wall St. research report covers Alkermes, Optimer, Questor and VIVUS. We have included the firm’s price target and the consensus price targets for some comparison.
Alkermes PLC (NASDAQ: ALKS) is already higher after its depression drug met its goals in Phase II studies. Merrill Lynch said that long-acting antipsychotics will be up 5% from a year ago, Vivitrol prescriptions are up 19% and even GLP-1 (Bydureon) is up 18% year over year. The firm rates this one only at Neutral, with a submarket target price of $24 for the stock. The Thomson Reuters consensus price target is also less than the $28.00 market price today, but Alkermes has seen a 9% gain on Wednesday.
Optimer Pharmaceuticals Inc. (NASDAQ: OPTR) was said to have IMS prescriptions of Dificid in March of 2,136, versus 1,998 in February. The firm noted that IMS data exclude hospital purchases of Dificid. Merrill Lynch rates Optimer as Underperform with only a $12.00 price target. Optimer shares trade at $14.65 today, and this stock has a $17.50 consensus price target.
Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) was shown to have its Acthar gel prescriptions down in March, versus February, but the firm expects that it will show sequential sales growth in the first quarter. This biotech is rated as Buy with a $40.00 price target over the next year. The consensus price target is all the way up at $45.38, versus a $27.36 price today.
VIVUS Inc. (NASDAQ: VVUS) was shown by Merrill Lynch that Qsymia prescriptions were projected to be 6,825, versus 5,481 in February. The firm said that yesterday’s FDA expansion should lead to an inflection in prescription growth before the end of 2013 and it expects additional longer term growth from that expanded formulary status. VIVUS is rated as rated as Buy at Bank of America, with a $24 12-month price target, and the consensus price target is $18.04, versus about $11.85 today.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
